Pazufloxacin Mesylate Sodium Chloride Injection

This product belongs to the quinolone antibacterial drug. Its main mechanism of action is to inhibit the activity of bacterial DNA gyrase and DNA topoisomerase IV, while its inhibitory effect on human DNA topoisomerase II is weak. This product has the characteristics of a broad antibacterial spectrum and strong antibacterial activity. Its antibacterial activity against aerobic, facultative anaerobic and anaerobic Gram-positive and -negative bacteria is the same as that of imipenem and ciprofloxacin, and it has a wider antibacterial spectrum than ceftazidime and gentamicin sulfate. It has strong antibacterial activity against various Gram-positive bacteria including clinically isolated Staphylococcus, Enterococcus, Pseudomonas aeruginosa, Bacteroides fragilis and Prevotella. In addition, this product shows strong antibacterial activity against intestinal bacteria resistant to imipenem, cefazolin or ceftazidime, ampicillin-resistant Haemophilus influenzae, Pseudomonas aeruginosa resistant to single-dose imipenem and gentamicin or two or three-dose drugs with ceftazidime added, imipenem-degrading β-lactamase-producing Serratia marcescens and Pseudomonas aeruginosa. This product has a bactericidal effect on Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, especially this product has a stronger bactericidal effect than ceftazidime and gentamicin in any period of the initial stationary period, logarithmic growth period, and stable period of Pseudomonas aeruginosa.

Pazufloxacin mesylate.

The product is effective for the following moderate and severe infections caused by sensitive bacteria among Staphylococcus, Streptococcus, Enterococcus, Neisseria, Haemophilus, Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Serratia, Proteus, Morganella, Providencia, Haemophilus influenzae, Pseudomonas aeruginosa, Acinetobacter, and Bacteroides: 1. Respiratory system infections: acute bronchitis, acute infection of chronic bronchitis, purulent tonsillitis, peritonsillar abscess, pneumonia, lung abscess, and concurrent infection of chronic respiratory diseases; 2. Urinary system infections: acute urethritis, acute cystitis, acute pyelonephritis, acute exacerbation of chronic pyelonephritis, complicated urinary tract infection, acute bacterial prostatitis, etc.; 3. Gynecological infections: adnexitis, uterine

Intravenous drip, twice a day for adults, 300 mg each time (calculated as pazufloxacin). For patients with severe infection and those whose pathogens are less sensitive to this product, the dose may be increased as appropriate.

During medication, gastrointestinal symptoms such as diarrhea, loose stools, nausea, vomiting, and other symptoms may occur; neurological symptoms such as headache, dizziness, and rash may occur. Transient liver function abnormalities may also occur, such as increased serum transaminase and total bilirubin. Occasionally, blood urea nitrogen increases, eosinophilia, and fever may occur.

[Use in pregnant and lactating women] Pregnant and lactating women are prohibited from using this drug. [Use in children] Patients under 18 years old are prohibited from using this drug. [Use in the elderly] When elderly patients use this drug, the blood concentration and urine excretion results should be checked. When Cmax increases, AUC increases, and urine recovery rate decreases, pay attention to the dosage and use the drug with caution.

Precautions for children: Children are prohibited from using this product. Precautions for pregnant and lactating women: Precautions for pregnant and lactating women. Precautions for the elderly: When elderly patients use this product, they should check the blood concentration and urine excretion results. When Cmax increases, AUC increases, and urine recovery rate decreases, pay attention to the dosage and use the drug with caution.

1. When used simultaneously with theophylline, symptoms of theophylline poisoning (digestive organ disorders, headache, arrhythmia, spasm, etc.) may occur. Therefore, avoid using it simultaneously with theophylline. If it is necessary to use it simultaneously, the blood concentration of theophylline should be fully observed and monitored. 2. When used simultaneously with phenylacetic acid and propionic acid non-steroidal anti-inflammatory analgesics, spasm may occur. When symptoms occur, the above drugs should be stopped and rescue measures such as tracheal antispasmodics should be implemented.

Keep away from light, sealed and stored in a dry place.

100 ml: 0.3 g of pazufloxacin and 0.9 g of sodium chloride